Company intelligence / Profile preview
Mabscale
Togliatti, Samara, Russiamabscale.ru ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Mabscale has several biosimilar monoclonal antibody products in its pipeline. Its lead programs include an adalimumab biosimilar for plaque psoriasis and MS‑011 for neoplasms, both at Phase 3. A rituximab biosimilar is in Phase 1 trials for rheumatoid arthritis. The company also has additional candidates at preclinical stages.
- Therapeutic areas
- OncologyImmunologyDermatology
- Modalities
- Monoclonal antibodyRecombinant proteinBiosimilar
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
UGA Biopharma GmbH (in-license of CHO-based cell lines/technology transfer)OCT Clinical (CRO partner for clinical trials)
Beyond the preview
Go deeper on Mabscale.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mabscale.